30 Stocks Moving In Monday's Mid-Day Session

Gainers

• Yield10 Bioscience Inc YTEN shares gained 280 percent to $7.41 after the company reported granting of research license to Monsanto for evaluation of 2 novel yield traits in soybean.
• ARGENX SE/S ADR ARGX shares jumped 55 percent to $47.19 after the company reported positive topline results from Phase 2 proof-of-concept trial of ARGX-113 in generalized myasthenia gravis.
• Net Element Inc NETE shares climbed 52.1 percent to $6.13.
• Shineco Inc TYHT shares rose 23.3 percent to $3.23 after the company disclosed a Share Exchange and Acquisition deal with Western Xinjiang Tiansheng Agricultural Development Co.
• Riot Blockchain Inc RIOT shares jumped 19.6 percent to $18.98 after gaining 8.63 percent on Friday.
• bluebird bio Inc BLUE shares gained 18.9 percent to $203.49 after the company announced updated clinical results from ongoing Phase 1 multicenter study of LentiGlobin gene therapy in severe sickle cell disease at the ASH2017.
• Famous Dave's of America, Inc. PLAY shares rose 18.9 percent to $6.30.
• Overstock.com Inc OSTK surged 17.7 percent to $53.05 following 13G filing from Morgan Stanley late Friday showing increased stake from 130,000 shares to 2.87 million shares.
• Blueprint Medicines Corp BPMC surged 17 percent to $84.07 after the company announced new data from ongoing Phase 1 clinical trial of Avapritinib.
• Seven Stars Cloud Group Inc SSC jumped 14.7 percent to $2.81.
• SunPower Corporation SPWR climbed 14.5 percent to $9.55. Baird upgraded SunPower from Neutral to Outperform.
• Clearside BioMedical, Inc. CLSD gained 13.6 percent to $6.6933.
• Intersect ENT Inc XENT shares rose 13.1 percent to $32.35 as the company reported the FDA approval of SINUVA Sinus Implant as a treatment option for recurrent nasal polyps.
• CHF Solutions Inc CHFS shares gained 12.8 percent to $3.87 after climbing 11.00 percent on Friday.
• U.S. Global Investors, Inc. GROW shares rose 12.2 percent to $4.43.
• Helios and Matheson Analytics Inc HMNY climbed 10.4 percent to $9.33 following news of a new marketing and performance-based sales deal with a movie distributor.
• Sunesis Pharmaceuticals, Inc. SNSS gained 8.5 percent to $2.69. Wells Fargo upgraded Sunesis Pharmaceuticals from Market Perform to Outperform.
• Marathon Patent Group Inc MARA gained 8.2 percent to $4.77 after declining 3.71 percent on Friday.
• Catalyst Biosciences Inc CBIO climbed 7.7 percent to $8.12 as the company announced promising interim Phase 1/2 CB 2679D/ISU304 results at the ASH2017.
• Trade Desk Inc TTD rose 7.5 percent to $48.64. SunTrust Robinson Humphrey upgraded Trade Desk from Hold to Buy.

Losers

• Spark Therapeutics Inc ONCE shares dipped 42.1 percent to $42.50 on volatile factor VIII activity data in hemophilia A gene therapy.
• Syros Pharmaceuticals Inc SYRS tumbled 37.3 percent to $7.76 following presentation at the ASH 2017 on Phase 2 trial of SY-1425 in genomically defined AML and MDS patients.
• Athenex Inc ATNX shares dropped 16.3 percent to $13.37.
• Juno Therapeutics Inc JUNO dipped 12.2 percent to $51.49. Juno Therapeutics and Celgene released additional data from the TRANSCEND trial of JCAR017 in patients with relapsed or refractory aggressive B-cell non-hodgkin lymphoma.
• Anavex Life Sciences Corp AVXL shares declined 11.7 percent to $3.26. Anavex Life Sciences reported FY17 loss of $0.33 per share, versus a year-ago loss of $0.42 per share.
• Trillium Therapeutics Inc TRIL shares fell 9.8 percent to $10.15
• Verastem Inc VSTM shares declined 8.5 percent to $3.96 after the company announced clinical data from the pivotal Phase 3 DUO study.
• Global Blood Therapeutics Inc GBT dropped 8.5 percent to $41.88 after the company released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition.
• Intevac, Inc. IVAC shares dropped 8.1 percent to $6.30 after gaining 0.74 percent on Friday.
• Seattle Genetics, Inc. SGEN shares fell 7 percent to $55.11. Seattle Genetics highlighted five-year survival results from Phase 1 trial of ADCETRIS in frontline mature T-cell lymphoma at the ASH 2017.